Currently, two innovators are dominating the $50 billion market : Novo Nordisk’s Ozempic or Wegovy (Semaglutide) and Eli ...

Susan McGowan, 58, from Lanarkshire, died from multiple organ failure, septic shock and pancreatitis after taking two ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Nvidia topping Apple as the most valuable company in the world and joining the Dow Jones Industrial Average. Why Novo Nordisk ...

Use of the weight loss drug was also linked to shorter hospital stays. Eli Lilly and Novo Nordisk are the main players in the GLP-1 field, but they're facing competition from compounding pharmacies, ...

Novo Nordisk's (NVO) third-quarter earnings were solid enough to soothe investor jitters and turn the market's attention toward upcoming trial results for a potentially game-changing new weight-loss ...

The medications include GLP-1 drugs such as Ozempic from Novo Nordisk and Trulicity from Eli Lilly, and SGLT2 drugs such as ...

Drugmaker Lupin aims to be part of the first wave of generic drugmakers to make GLP-1 receptor agonists products, used to ...

"It's important that patients are aware that Novo Nordisk is the only company in the U.S. with FDA-approved medicines containing the main ingredient semaglutide. FDA has not approved any generic ...

Zealand Pharma A/S briefly reclaimed its position as this year’s best performer in the Stoxx 600 Health Care Index on Friday, ...

Currently, Hims & Hers can offer compounded semaglutide due to the patent-related supply shortages affecting patent holders ...